Rivera-Chaparro Nazario D, Cohen-Wolkowiez Michael, Greenberg Rachel G
Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Department of Pediatrics, Duke University, Durham, NC 27710, USA.
Future Microbiol. 2017 Sep;12(11):1001-1016. doi: 10.2217/fmb-2017-0058. Epub 2017 Jul 31.
Antibiotics are often used in neonates despite the absence of relevant dosing information in drug labels. For neonatal dosing, clinicians must extrapolate data from studies for adults and older children, who have strikingly different physiologies. As a result, dosing extrapolation can lead to increased toxicity or efficacy failures in neonates. Driven by these differences and recent legislation mandating the study of drugs in children and neonates, an increasing number of pharmacokinetic studies of antibiotics are being performed in neonates. These studies have led to new dosing recommendations with particular consideration for neonate body size and maturation. Herein, we highlight the available pharmacokinetic data for commonly used systemic antibiotics in neonates.
尽管药品标签中缺乏相关给药信息,但抗生素仍经常用于新生儿。对于新生儿给药,临床医生必须从针对成年人和大龄儿童的研究中推断数据,而这些人群的生理机能显著不同。因此,剂量推断可能会导致新生儿中毒风险增加或疗效不佳。受这些差异以及近期强制要求开展儿童和新生儿药物研究的法规推动,越来越多针对新生儿的抗生素药代动力学研究正在进行。这些研究已产生了新的给药建议,特别考虑了新生儿的体型和发育情况。在此,我们重点介绍新生儿常用全身性抗生素的现有药代动力学数据。